Driehaus Capital Management 13F: Adds $4.3M to PRAX Stake

Driehaus Capital Management Boosts Stake in Praxis Precision Medicines

Driehaus Capital Management expanded its position in Praxis Precision Medicines, Inc. (NasdaqGS: PRAX), lifting its holdings by 1.7% during the quarter. According to its latest Form 13F filing with the Securities and Exchange Commission, the fund added 16,164 shares to bring its total ownership to 949,225 shares. Based on market prices around the filing date, the stake was valued at approximately $253 million. Because 13F filings look backward at a prior quarter, this position may not reflect the fund's current share count today.

Praxis Precision Medicines Stock Performance

The company's shares change hands around $266.58, moving within a wide 52-week band that stretches from a low of $46.61 up to a high of $392.70. The biotechnology firm commands a market value in the billions, while holding strong liquidity metrics to support its ongoing clinical trials.

Insider Buying and Selling at Praxis Precision Medicines, Inc.

Company insider Jill Desimone completed transactions on June 24, 2026, acquiring 11,600 shares at an average price of $71.20 per share for a total of $825,953.64, while also disposing of 11,600 shares on the same date.

Wall Street Analyst Views on Praxis Precision Medicines

Wall Street firms continue to keep an optimistic posture toward the biotechnology developer. On October 16, 2026, JP Morgan initiates the stock with an Overweight rating and a $700.00 price target. A day earlier on October 15, 2026, UBS initiates coverage with a Buy rating and a $706.00 price target. Also on October 15, 2026, HC Wainwright & Co. reiterates its Buy rating with a $1,201.00 price target, matching its earlier note from October 6, 2026. BTIG maintains its Buy rating on October 6, 2026, moving its price target to $826.00. Earlier in the autumn, HC Wainwright & Co. reiterates a Buy rating with a $1,201.00 target on September 24, 2026, while Needham maintains a Buy rating with a $582.00 target on the same day. Goldman Sachs maintains a Buy rating on August 21, 2026, adjusting its target to $575.00.

About Praxis Precision Medicines

Based in Boston, Massachusetts, Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical firm focused on treatments for central nervous system disorders. The company applies proprietary discovery platforms to build a pipeline of oral and targeted therapies addressing conditions like essential tremor and epilepsy.

Looking Ahead for Praxis Precision Medicines

Investors should keep an eye out for upcoming regulatory updates and future periodic reports from institutional managers. As always, past 13F disclosures offer only a snapshot of institutional sentiment from a prior period.